Market Data 
Markets
Replies to post #192627 on Biotech Values
06/17/15 9:47 AM
06/17/15 10:48 AM
@matthewherper @DewDiligence To boot, other adverse events will emerge if - when? - Kybella is injected outside the submental area.
— Catherine SaintLouis (@cslwrites) June 17, 2015
07/06/15 10:57 AM
Allergan…and Oculeve…today announced that they have entered into an agreement under which Allergan will acquire Oculeve in an all-cash transaction. Under the terms of the agreement, Allergan will acquire Oculeve for a $125 million upfront payment and commercialization milestone payments related to Oculeve's lead development program OD-01. The agreement also includes the acquisition of an additional earlier-stage dry eye device development program. Allergan's 2015 earnings-per-share forecast provided on May 11, 2015 is unchanged as a result of the acquisition.
08/05/15 10:47 AM
Allergan PLC amended the terms of its pending $2.1 billion deal for double-chin treatment maker Kythera Biopharmaceuticals Inc. by agreeing to pay for it all in cash and dropping the stock component.
In a news release Wednesday, the companies expect the all-cash transaction at $75 a share can be completed more quickly than the original deal announced in June, which was comprised of 80% cash and 20% stock.
At the time, Allergan Chief Executive Brent Saunders said the maker of wrinkle-treatment Botox had opted against an all-cash deal to save “fire power for future deals” this year.
Since then, Allergan has agreed to sell its generics unit to Teva Pharmaceutical Industries Ltd. in a cash-and-stock deal valued at $40.5 billion, of which $33.75 billion is expected to be in cash.
AI
